5 recruiting, 3 completed, 1 active not recruiting, 1 not yet recruiting. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 5, Completed 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Leuprorelin: new trials by email Literature Review of Leuprorelin trials Research Report on Leuprorelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial Biospecimen Collection, Electronic Health Record Review, Goserelin - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 75 | 2026-01-22 | 2026-06-23 |
| A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer Elacestrant, Leuprorelin - Breast Cancer | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 140 | 2025-10-06 | 2025-12-01 |
| Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer Biospecimen Collection, Contrast Agent, Leuprolide - Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 70 | 2024-08-12 | 2026-03-09 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Leuprorelin - Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney | Phase 2 | Recruiting | University Medical Center Groningen | 36 | 2022-06-01 | 2022-11-04 |
| Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Doxorubicin, Cyclophosphamide, Docetaxel - Breast Cancer, Invasive Breast Cancer | Phase 2 | Unknown | National Cancer Center, Korea | 114 | 2017-05-08 | 2018-04-13 |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Bicalutamide, Degarelix, Docetaxel - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 612 | 2017-04-05 | 2026-09-14 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer Relugolix, Leuprorelin - Prostate Cancer | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 136 | 2014-03-26 | 2018-05-09 |
| Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer Paclitaxel, Bevacizumab, Letrozole - Metastatic Breast Cancer | Phase 2 | Completed | Japan Breast Cancer Research Group | 160 | 2014-01-01 | 2022-08-04 |
| Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 Leuprorelin, TAK-448 - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Millennium Pharmaceuticals, Inc. | 9 | 2010-11-01 | 2012-01-31 |
| Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c Leuprorelin, Flutamide - Prostatic Neoplasms | Phase 2 | Completed | Takeda | 341 | 1996-12-01 | 2015-07-29 |
Breast Neoplasms (5) · Prostatic Neoplasms (5) · Polycystic Kidney, Autosomal Dominant (1) · Polycystic liver disease (1)
Millennium Pharmaceuticals, Inc. (2) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hebei Medical University Fourth Hospital (1) · Japan Breast Cancer Research Group (1) · Mayo Clinic (1) · NRG Oncology (1) · National Cancer Center, Korea (1) · Ohio State University Comprehensive Cancer Center (1) · Takeda (1) · University Medical Center Groningen (1) · University of Michigan Rogel Cancer Center (1)
United States (5) · Canada (2) · France (2) · Japan (1) · Netherlands (1) · Puerto Rico (1) · South Korea (1)
Jacob J. Orme, MD, PhD (1) · Keun Seok Lee, MD, PhD (1) · Mark D Hurwitz (1) · Masakazu Toi, MD, PhD (1) · Norah L Henry (1) · Shang-Jui Wang, MD, PhD (1) · Shigehira Saji, MD, PhD (1)
2009 (1), R01CA286127 (1), R01CA300454 (1), U10CA180868 (1)